Pharmaceuticals, Biotechnology and Life Sciences
DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Migraine” report has been added to ResearchAndMarkets.com’s offering. This Market Spotlight report covers the Migraine market,…
BALERNA, Switzerland–(BUSINESS WIRE)–APR Applied Pharma Research’s patented formulation of Diclofenac 50 mg powder oral solution for migraine treatment and other…
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for Novartis’s Aimovig…
Amgen’s Phase 3b study called Liberty, in co-development with Novartis, aimed to test Aimovig for treating migraine, has met it’s…
Eli Lilly has bought a biotech company focusing on pain management, CoLucid Pharmaceuticals for approximately $960 million, ($46.50 per share)…
Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Sosei Group’s subsidiary Heptares, for the treatment of migraine.